| You are here: Home: BCU 2|2004: I Craig Henderson, MD, FACP, FRCP: Select publications
Select publications
Publications discussed by Dr Henderson
Albain KS et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100 (SWOG-8814). Proc ASCO 2002;Abstract 143.
Albain KS et al. Overall survival after cyclophosphamide, Adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: New findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100). Proc ASCO 2002;Abstract 94 .
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9. Abstract
Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract
Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 3.
Boccardo F et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001;19(22):4209-15. Abstract
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract
Jones S et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Can Res Treat 2003;82(Suppl 1):9;Abstract 10.
Martin M et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 43.
|
